Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in gliomaNEURO-ONCOLOGYIF13.42019-04-1921OAAI
A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain TumorsNEOPLASIAIF7.72018-05-0120OAAI
Cyclin dependent kinase 7 represents a promising therapeutic target in gliomaCANCER RESEARCHIF16.62017-07-010PRE
Cyclin-dependent kinase 7 is a therapeutic target in high-grade gliomaONCOGENESISIF6.42017-05-1566OAAI
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implicationsONCOGENEIF7.32015-02-0949OAAI
Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivoONCOGENEIF7.32014-04-2121OAAI
Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell GrowthOBSTETRICS AND GYNECOLOGYIF4.72013-10-0124PREAI
Promiscuous transactivation of multiple receptor tyrosine kinases by EGFR mutations: mechanism and therapeutic significance.CANCER RESEARCHIF16.62013-04-010PRE
Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with CancerJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92013-01-0136OAAI
C-Met antibodies with distinctive characteristics including induction of receptor degradation without activation and tumor specificityCANCER RESEARCHIF16.62011-04-011PRE
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向